glp-1 vs gip Major physiological roles of and GIP. Tirzepatide is acting as an... Beyond the pancreas: contrasting cardiometabolic
Description
Discover the serious yet rare side effects of Ozempic, including pancreatitis, thyroid cancer, and more, plus expert insights.
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options to reach the market and help address a shortage.
Recent signals underscore this shift: Eli Lilly became the first pharmaceutical company to surpass a $1 trillion market capitalization [1] buoyed by global demand for obesity medications
Here, we highlight the mechanisms linking T2DM and PD, as well as the links between insulin resistance (IR) and PD patients risk of developing cognitive deficits
The GLP-1 market has faced supply constraints in recent months as drugs like Ozempic and Wegovy continue to skyrocket in popularity.
Starting Jan.1, 2026, Pennsylvania will limit GLP1 weightloss drugs under Medicaid threatening access for thousands of lowincome patients.
